Journal of Clinical Oncology, Vol 10, 249-256, Copyright © 1992 by American Society of Clinical Oncology
Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study
HS Friedman, JP Krischer, P Burger, WJ Oakes, B Hockenberger, MD Weiner, JM Falletta, D Norris, AH Ragab and DH Mahoney Jr
Duke University Medical Center, Durham, NC.
PURPOSE: The Pediatric Oncology Group (POG) conducted a randomized phase II
study to evaluate the activity of carboplatin and iproplatin in children
with progressive or recurrent brain tumors. PATIENTS AND METHODS: The study
was designed to evaluate the activity of these agents and to compare the
toxicities associated with their use. Treatment consisted of carboplatin
560 mg/m2 at 4-week intervals or iproplatin 270 mg/m2 at 3-week intervals.
RESULTS: The major toxicity observed was myelosuppression, particularly
thrombocytopenia, for both agents. Ototoxicity (grade 1 or 2) was seen in
2.5% of patients treated with carboplatin and 1.3% of patients treated with
iproplatin. The majority of patients with low-grade astrocytic neoplasms
treated with carboplatin (nine of 12 patients) or iproplatin (eight of 12
patients) demonstrated tumor response or prolonged stable disease that
persisted off-therapy. The duration of stable disease produced by
carboplatin was particularly striking, ranging from 2 months to 68 + months
(median, 40 + months). Neither drug demonstrated appreciable activity in
the treatment of medulloblastoma (two of 26 responses to carboplatin, one
of 14 responses to iproplatin), ependymoma (two of 17 responses to
carboplatin, none of seven responses to iproplatin), high-grade glioma (two
of 19 responses to carboplatin, one of 14 responses to iproplatin), or
brain-stem tumors (one of 23 responses to carboplatin, none of 14 responses
to iproplatin). CONCLUSION: Carboplatin is active against low-grade
gliomas. Further evaluation of the role of carboplatin in the
preirradiation treatment of children with low-grade gliomas of the optic
pathway is currently underway in a clinical trial.
This article has been cited by other articles:
|
|
|
|
 
M. Fouladi, M. Chintagumpala, F. H. Laningham, D. Ashley, S. J. Kellie, J. W. Langston, C. W. McCluggage, S. Woo, M. Kocak, K. Krull, et al.
White Matter Lesions Detected by Magnetic Resonance Imaging After Radiotherapy and High-Dose Chemotherapy in Children With Medulloblastoma or Primitive Neuroectodermal Tumor
J. Clin. Oncol.,
November 15, 2004;
22(22):
4551 - 4560.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Quinn, D. A. Reardon, A. H. Friedman, J. N. Rich, J. H. Sampson, J. M. Provenzale, R. E. McLendon, S. Gururangan, D. D. Bigner, J. E. Herndon II, et al.
Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma
J. Clin. Oncol.,
February 15, 2003;
21(4):
646 - 651.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Gururangan, C. M. Cavazos, D. Ashley, J. E. Herndon II, C. S. Bruggers, A. Moghrabi, D. L. Scarcella, M. Watral, S. Tourt-Uhlig, D. Reardon, et al.
Phase II Study of Carboplatin in Children With Progressive Low-Grade Gliomas
J. Clin. Oncol.,
July 1, 2002;
20(13):
2951 - 2958.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. H. Athale, C. Stewart, J. F. Kuttesch, A. Moghrabi, W. Meyer, C. Pratt, A. Gajjar, and R. L. Heideman
Phase I Study of Combination Topotecan and Carboplatin in Pediatric Solid Tumors
J. Clin. Oncol.,
January 1, 2002;
20(1):
88 - 95.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A Walker, J. A G Punt, and M. Sokal
Clinical management of brain stem glioma
Arch. Dis. Child.,
June 1, 1999;
80(6):
558 - 564.
[Full Text]
|
|
|
|
|
|
|
R. J. Packer and J. L. Finlay
Chemotherapy for Childhood Medulloblastoma and Primitive Neuroectodermal Tumors
Oncologist,
December 1, 1996;
1(6):
381 - 393.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
